The Shortage Designation Is Over
In early 2025, the FDA formally declared that the semaglutide shortage — which had allowed 503A and 503B compounding pharmacies to produce semaglutide for patients since 2022 — was resolved. This triggered immediate enforcement implications for the large ecosystem of compounding pharmacies that had built businesses around compounded GLP-1 agonists.
What Changes Practically
For patients currently using compounded semaglutide: The FDA began a transition period, giving patients and prescribers time to switch to brand-name Wegovy or Ozempic. 503A pharmacies generally have until late 2025 to cease compounding semaglutide for standard formulations. Patient-specific needs (documented allergy to excipients, required strength not commercially available) may still qualify under narrower 503A provisions.
For 503B outsourcing facilities: These facilities face similar phaseout requirements, with slightly different timelines and scope. Some are challenging the FDA’s shortage determination in court.
For prescribers: Physicians who were prescribing compounded semaglutide through telemedicine or clinic channels need to transition patients to brand-name products or document patient-specific need that would qualify for the 503A exemption.
What Hasn’t Changed
The underlying evidence for semaglutide remains unchanged. The STEP and SELECT trials establishing semaglutide’s efficacy and cardiovascular benefit are not affected by this regulatory action. Brand-name Wegovy and Ozempic remain FDA approved and available.
Access and cost remain the key challenges. Brand-name semaglutide without insurance coverage can exceed $1,000/month. This cost differential was a primary driver of compounding demand.
The Legal Landscape
Multiple compounding pharmacies have challenged the FDA’s shortage determination in federal court, arguing that the shortage is not truly resolved given ongoing supply constraints and patient access issues. Litigation is ongoing as of this writing. The regulatory situation will continue to evolve.
Tirzepatide Status
Tirzepatide (Zepbound/Mounjaro) was following a similar trajectory — on shortage designation, allowing compounding, with enforcement action anticipated as that shortage resolves. Check current status with your pharmacy or prescriber, as the timeline was still uncertain at publication.
What This Means for Patients
If you have been using compounded semaglutide and it has been working, talk to your prescriber about:
- Transitioning to brand-name Wegovy (for weight management) or Ozempic (for diabetes)
- Insurance coverage options and manufacturer copay assistance programs
- Whether you have a documented patient-specific need that might qualify for continued compounding
The efficacy you’ve experienced from compounded semaglutide should translate directly to the brand-name product — the active ingredient is the same.
This article reflects information available as of March 2025. Regulatory status changes frequently. Verify current guidance with a licensed pharmacist or attorney.